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ABSTRACT 
 
Fc receptors (FcRs) are expressed on the surface of all types of cells of the immune system. They bind the 
Fc portion of immunoglobulin (Ig), thereby bridging specific antigen recognition by antibodies with cellu-
lar effector mechanisms. FcγRIIA, one of the three receptors for human IgG, is a low-affinity receptor for 
monomeric IgG, but binds IgG immune complexes efficiently. FcγRIIA is believed to play a major role in 
eliciting monocyte- and macrophage-mediated effector responses against blood-stage malaria parasites. A 
G → A single nucleotide polymorphism, which causes an arginine (R) to be replaced with histidine (H) at 
position 131,  defines two allotypes  which difer in their  avidity for  complexed  human IgG2 and  IgG3. 
Because  FcγRIIA-H131  is  the  only  FcγR  allotype  which  interacts  efficiently  with  human  IgG2,  this 
polymorphism  may  determine  whether  parasite-specific  IgG2  may  or  may  not  elicit  cooperation  with 
cellular imune responses during blood-stage malaria infection. Here, we review data from four published 
case-control studies describing associations between FcγRIIA R/H131 polymorphism and malaria-related 
outcomes and discuss possible reasons for some incongruities found in these available results. 
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INTRODUCTION 
 
Fc receptors (FcRs) belong to the family of immunorecep-
tors, which includes T-cell receptors, B-cell receptors and 
natural killer (NK) receptors. These glycoproteins are ex-
pressed on the surface of all types of cells of the immune 
system; they bind the Fc portion of immunoglobulin (Ig), 
thereby bridging specific antigen recognition by antibodies 
with cellular effector mechanisms. The FcRs are essential 
molecules in the host defense against infection. Interaction 
between antibodies of a given class and the corresponding 
FcR elicits a variety of cellular responses, such as phago-
cytosis and endocytosis, antibody-dependent cell-mediated 
cytotoxicity  (ADCC),  generation  of  superoxide  radicals 
and  release  of  pro-inflammatory  cytokines  (Fleisch  and 
Neppert, 2000). Specific FcRs are known for each class of 
human  Ig,  but  FcγRI  (CD64),  FcγRII  (CD32),  FcγRIII 
(CD16) and FcεRI form a subset of more closely related 
molecules within the immunoglobulin superfamily (Kinet, 
1999; Ravetch and Bolland, 2001; Monteiro and van der 
Winckel, 2003).  
 
The  three  classes  of  human  FcγRs  comprise  several 
isoforms (FcγRIA, -B and -C; FcγRIIA, -B and -C, and 
FcγRIIIA and -B), which differ in their binding affinity to 
different human IgG subclasses and levels of expression 
on  different  cell  types.  The  low-affinity  isoforms 
(FcγRIIA,  -IIB,  -IIC,  -IIIA  and  -IIIB)  co-localize  to  a 
region  on  chromosome  1q23  which  includes  the  genes 
coding for C-reactive protein, a family of FcR homologues 
and the Duffy blood group (Su et al, 2002). Members of 
the FcγRII class differ from those of other FcγR classes in  
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that they comprise either activitory (ITAM) or inhibitory 
(ITIM)  signaling  motifs  within  their  respective  ligand-
binding chains (Gessner et al, 1998). FcγRIIA is a low-
affinity  receptor  for  monomeric  IgG  (KA  <10
7/M),  but 
binds  IgG immune complexes efficiently. It is the  most 
widely distributed FcγR isoform, being expressed on the 
surface  of  virtually  all  myeloid  cells,  including 
mononuclear  phagocytes,  neutrophils  and  platelets.  This 
receptor  plays  critical  roles  in  the  removal  of  immune 
complexes,  activation  of  inflammatory  cells  and 
phagocytosis of antibody-coated microorganisms (Ravetch 
and Bolland, 2001).  
 
Fcγ γ γ γRIIA polymorphism 
FcγRIIA displays a funcionally relevant G → A single 
nucleotide  polymorphism  in  the  region  encoding  its 
ligand-binding domain, which causes an arginine (R) to 
be  replaced  with  histidine  (H)  at  position  131  of  its 
extracellular  domain.  Both  allotypes  avidly  bind 
complexed  human  IgG3  and  IgG1,  but  the  FcγRIIA-
H131 allotype displays a higher affinity for human IgG2 
and IgG3 than the FcγRIIA-R131 allotype; none of them 
bind  IgG4  efficiently.  Because  FcγRIIA-H131  is  the 
only FcγR which interacts efficiently with human IgG2, 
this  allotype  is  essential  for  the  clearance  of  IgG2-
containing immune complexes (Salmon et al, 1996) and 
phagocytosis  of  IgG2-opsonised  microorganisms 
(Sanders et al, 1995). As a consequence, the FcγRIIA-
R/H131 polymorphism is associated with predisposition 
to  autoimmune  diseases  such  as  systemic  lupus 
erythematosus  and  antiphospholipid  syndrome,  which 
may be mediated by the deposition of IgG2-containing 
immune complexes (Karassa et al, 2004), and infections 
caused  by  encapsulated  bacteria,  whose  clearance 
largely  depends  on  IgG2-mediated  phagocytosis 
(Rodriguez et al, 1999; Jansen et al, 1999).  A second 
polymorphic site has been described in FcγRIIA: a CA 
→ GA mutation results in glutamine or tryptophan in its 
membrane-distal  Ig-like  domain.  This  amino  acid 
replacement,  however,  does  not  affect  the  receptor 
avidity for IgG (Warmerdam et al, 1990).   
 
The  distribution  of  the  FcγRIIA-H131  and  -R131 
allotypes vary widely among ethnic groups. H131/H131 
homozygotes are more frequent among Eastern Asians 
than Caucasians (Lehrnbecher et al, 1999), being rare in 
Amazonian  Amerindians  (Kuwano  et  al,  2000). 
Differences  in  allotype  frequencies  of  FcγRIIA-H131 
and other linked genes are believed to account for part 
of the variation in the prevalence of some autoimmune 
and infectious diseases among ethnic groups.    
 
IgG  subclasses  and  naturally  acquired  immunity  to 
malaria 
Malaria parasites are major human pathogens associated 
with 300-500 million clinical cases worldwide and 0.5-
3 million deaths each year, mostly among children un-
der the age of five years living in sub-Saharan Africa 
(Guerin et al, 2002). Human malaria is caused by four 
species of parasitic protozoa of the genus Plasmodium: 
P. falciparum, P. vivax, P. malariae and P. ovale. The 
natural  history  of  infection  with  P.  falciparum,  that 
causes  most  severe  infections  and  nearly  all  malaria-
related deaths, has been well characterised in areas of 
high endemicity in Africa (Day and Marsh, 1991). In-
fants  have  a  primary  malaria  attack  during  their  first 
year of life, while most toddlers and juveniles have al-
ready  developed  tolerance  against  severe  disease,  but 
still experience a few clinical episodes. African adoles-
cents  and  adults,  in  contrast,  are  often  clinically  im-
mune;  they  remain  free  of  malaria  symptoms  despite 
continuous exposure to the parasite, but maintain low-
grade  infections  throughout  the  transmission  season. 
Clinical immunity is usually lost during pregnancy, es-
pecially  among  primigravidae,  or  after  migration  to 
non-endemic areas. Life-long exposure to malaria para-
sites rarely leads to sterile immunity; blood-stage infec-
tions remain detectable by sensitive methods in all age 
groups.  
 
The  acquisition  of  immunity  to  blood-stage  malaria 
parasites, after several years of continuous exposure to 
intense  transmission,  depends  on  both  antibody-  and 
cell-mediated mechanisms. The gradual switch towards 
Igs  of  both  IgG1  and  IgG3  subclasses,  which  bind 
efficiently to all classes and isoforms of FcγR present 
on  the  surface  of  effector  cells  such  as  monocytes, 
macrophages and neutrophils, is believed to play a key 
role  in  this  process.  The  binding  of  cytophilic 
antibodies  to  effector  cells  triggers  parasite-killing 
effector  responses,  such  as  opsonisation  and 
phagocytosis of extracellular parasites or parasitised red 
blood  cells  (pRBC)  (Ferrante  et  al,  1990;  Groux  and 
Gysin, 1990) and the ADCC-like mechanism known as 
antibody-dependent  cellular  inhibition  (ADCI)  of 
intracellular parasites (Bouharoun-Tayoun et al, 1990) 
(Figure 1).  Since both ADCI and the opsonising effect 
of cytophilic antibodies are competitively inhibited, in 
vitro, by non-cytophilic IgG2 and IgG4 antibodies with 
the  same  specificities  (Groux  and  Gysin,  1990; 
Bouharoun-Tayoun  and  Druilhe,  1992),  the  subclass 
balance may be a decisive factor in naturally acquired 
immunity to malaria: protected and unprotected subjects 
could  be  differentiated  by  the  relative  levels  of 
cytophilic  antibodies  recognising  parasite  antigens 
(Bouharoun-Tayoun and  Druilhe,  1992;  Ferreira  et  al, 
1996).  
 
Because ADCI is known to be mediated by FcγRII (but 
not  FcγRI)  on  the  surface  of  monocytes  (Bouharoun-
Tayoun et al, 1995), FcγRII polymorphisms that alter the 
affinity  of  this  receptor  for  some  IgG  subclasses  are 
expected to modulate the efficiency of monocyte-mediated 
parasite  killing.  Non-immune  or  partially  immune 
subjects, for example, tend to produce predominantly IgG 
antibodies  of  the  IgG2  subclass  during  acute  malaria 
infections (Wahlgren et al, 1983; Ferreira et al, 1996), and 
this subclass bias has been associated with poor clinical 
immunity  (Bouharoun-Tayoun  and  Druilhe,  1992). 
Although  often  regarded  as  blocking  antibodies  (Groux 
and Gysin, 1990; Bouharoun-Tayoun and Druilhe, 1992), 
these specific IgG2 antibodies might elicit both ADCI and 
phagocytosis  by  engaging  effector  cells  carrying  the 
FcγRIIA-H131 allotype (Aucan et al, 2000).   
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Figure 1. Antibody-dependent cellular mechanisms involved in Plasmodium falciparum blood stage killing. (A) Classical phagocy-
tosis of parasitised red blood cells (pRBC). (B) Antibody-dependent cellular inhibition (ADCI). ADCI is an ADCC-like effect which 
inhibits the growth of young asexual blood-stages within erythrocytes through the release of soluble factors (such as tumour necrosis 
factor [TNF]-α and interferon [IFN]-γ) by monocytes (MN). This mechanism is triggered by the recognition of merozoite surface 
antigens by IgG, which interacts with MN via their FcγRIIA receptors. Panel B adapted from Druilhe and Pérignon (1997). 
 
 
More than 70% of the African-American subjects so far 
typed are either homozygous or heterozygous for the H131 
allele (Lehrnbecher et al, 1999); quite similar H131 allele 
frequencies have seen found in malaria-exposed African 
populations (Aucan et al, 2000; Shi et al, 2001; Cooke et 
al, 2003; Brouwer et al, 2004). An FcγRIIA with increased 
affinity for human IgG2 and IgG3, in subjects carrying the 
H131  allele,  implies  that  FcγRIIA-dependent  parasite-
killing  responses  might  be  more  efficiently  elicited  by 
specific  antibodies  of  these  subclasses.  Accordingly, 
FcγRIIA-mediated phagocytosis in vitro, following pRBC 
opsonisation  with  IgG3,  is  more  efficient  in  human 
monocytes of the H131 allotype than in those of the R131 
allotype (Tebo et al, 2002). Even more evident differences 
between  FcγRIIA  allotypes  are  expected  in  relation  to 
IgG2-mediated  protection.  In  fact,  IgG2  antibodies  to 
surface  malarial  antigens  confer  significant  protection 
against  blood-stage  infection  and  clinical  disease  in 
subjects carrying the H131 allele, but not in R131/R131 
homozygotes (Aucan et al, 2000). If H131 allele carriers 
acquire  IgG2-mediated  protection  from  blood-stage 
infection before the exposure-dependent switch to specific 
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antibodies of the IgG1 and IgG3 subclasses takes place, the 
FcγRIIA-H131 allotype  may  be  associated with  a  faster 
development  of  clinical  immunity  leading  to  reduced 
malaria morbidity in these subjects.   
 
Accordingly, in a recent cross-sectional survey in Brazil 
we found higher levels of IgG2 subclass antibodies to lo-
cally prevalent variants of the major malaria-vaccine can-
didate  antigen,  merozoite  surface  protein-2  (MSP-2), 
among  asymptomatic  carriers  of  P.  falciparum  than  in 
subjects  with  symptomatic  malaria  episodes  due  to  the 
same species. Antibodies of all other IgG subclasses were 
found  in  similar  concentrations  in  both  clinical  groups. 
Because  of  the  high  H131  allele  frequency  in  the  local 
population (83%), IgG2 antibodies to surface malaria anti-
gens  may  help  in  triggering  cell-mediated  immunity  to 
blood-stage parasites, via the FcγRIIA-H131 allotype, in 
the  majority  of  these  subjects  (Scopel  KKG  and  Braga 
EM, in preparation).  
Fcγ γ γ γRIIA-H131 allotype and malaria morbidity 
Four  published  case-control  studies  have  examined  the 
association between H/R131 FcγRIIA polymorphism and 
malaria morbidity in African and East-Asian populations 
(Table 1). Since different malaria-related outcomes were 
evaluated (high-density P. falciparum parasitaemia, severe 
malaria in children or adolescents and adults and placental 
malaria) in different ethnic and age groups, these studies 
are not strictly comparable. Significantly, however, none 
of  them reported an association  between  FcγRIIA-H131 
allotype carriage and protection from malaria morbidity, as 
it  could  be  expected  on  the  basis  of  a  putative  IgG2-
mediated protection against blood-stage parasites (Aucan 
et  al,  2000).  In  contrast,  R131/R131  homozygosity  was 
associated with protection against high-density parasitae-
mia in one study (Shi et al, 2001) and H131/H131 homo-
zygosity was associated with increased risk of either se-
vere/cerebral malaria or placental malaria in three studies 
(Omi et al, 2002; Cooke et al, 2003; Brouwer et al, 2004).
 
 
 
Table 1. Characteristics and main findings of four published case-control studies addressing the association between 
FcγRIIA polymorphism and Plasmodium falciparum malaria morbidity 
 
 
Country 
 
Comparison groups 
 
 
Main findings 
 
Reference 
 
Kenya 
 
High-risk
a (n = 97) and low-risk
b  (n = 85)
 
infants aged 1 year 
 
Significant excess of R131/R131 
homozygotes in the low risk group, when 
compared to H131/R131 heterozygotes; 
similar proportions of H131/H131 
homozygotes in both groups 
 
 
 
Shi et al, 2001 
Thailand  Patients aged > 13 years (mean, 25 years) 
with either cerebral malaria (n = 107), non 
cerebral severe malaria (n = 157) or mild 
malaria (n = 202) 
 
 
Significant excess of H131/H131 
homozygotes carrying the FcγRIIIB-NA2 
allotype
c among cerebral malaria patients, 
when compared to mild malaria controls 
Omi et al, 
2002 
Gambia  Children aged 0-10 years with either 
severe (n = 524) or mild malaria (n = 333) 
and non-infected controls (n = 558) 
 
 
Significant excess of H131/H131 
homozygotes among severe malaria 
patients, when compared to non-infected 
controls 
Cooke et al, 
2003 
Kenya  Pregnant women, either HIV-1 positive (n 
= 658) or not (n = 245), with (n = 285) or 
without (n = 618) placental malaria
d at 
delivery 
Significant excess of H131/H131 
homozygotes among HIV-1-positive 
women (but not among HIV-1-negative 
women) with placental malaria; similar 
proportions of R131/R131 homozygotes in 
both groups 
 
Brouwer et al, 
2004 
 
 
aHigh-risk infants had ≥ 30% of routine monthly blood smears positive for Plasmodium falciparum (parasite counts > 5000 parasites per microlitre) 
over their first year of life. 
bLow-risk infants had ≤ 8% of routine monthly blood smears positive for Plasmodium falciparum (parasite counts > 5000 parasites per microlitre) 
over their first year of life. 
cThe FcγRIIIB-NA2 allotype reduces the capacity for phagocytosis in neutrophils, when compared to the FcγRIIIB-NA1 allotype (Salmon et al, 
1990). The authors report no significant independent association between FcγRIIA or FcγRIIIB allotypes and cerebral malaria; a significant 
association only emerged when the simultaneous carriage of H131 and NA2 alleles was considered.  
dPlacental malaria was defined as the presence of malaria parasites in blood samples obtained, at delivery, from a shallow incision on the maternal 
side of the placenta.  
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Therefore,  H131/H131  homozygosity  emerged  as  a  risk 
factor  for  malaria  morbidity  in  three  different  popula-
tionss, and R131/R131 homozygosity was associated with 
protection from high-density parasitaemia in one popula-
tion. These unexpected findings could be tentatively ex-
plained as a consequence of an increased activation of the 
immune system, due to the engagement of FcγRIIA-H131 
by a broader repertoire of IgG subclasses, leading to the 
release  of  large  amounts  of  pro-inflammatory  cytokines 
and therefore to immunopathology and disease (Cooke et 
al, 2003). High frequencies of the H131 allele could have 
been maintained in malaria-exposed  African  populations 
as a result of a delicate balance between negative selection 
(due to the increased risk of severe malaria) and positive 
selection  (due  to  reduced  morbidity  and  mortality  from 
infections with encapsulated bacteria) (Cooke et al, 2003).  
Alternatively, this may represent a spurious causal associa-
tion  resulting  from  linkage  disequilibrium  between  the 
FcγRIIA-H131 allotype and other genetic determinants of 
malaria morbidity. 
 
Further speculations are limited by the lack of more ap-
propriate data. No longitudinal study, for example, has so 
far  examined  the  combined  effects  of  H/R131  FcγRIIA 
polymorphism and  levels  of  IgG2  antibodies  to  malarial 
antigens upon malaria morbidity. Polymorphisms in other 
linked genes, such as FcγRIIIB, should be examined and 
adjusted for in risk analysis. Age represents an important 
factor: infants are less likely to benefit from the ability of 
the  FcγRIIA-H131  allotype  to  bind  malaria  parasite-
specific  IgG2  than  older  children  and  adults,  since  they 
tend to produce low levels of antibodies of this subclass in 
response to antigenic stimuli (Bird et al, 1985). Adult con-
centrations of IgG2 are usually reached at the age of 10 
years (Maguire et al, 2002), but children living in areas of 
intense malaria transmission are already clinically immune 
and rarely experience severe disease at this age (Day and 
Marsh, 1991). Experimental murine malaria models cannot 
provide valuable information, as no FcγRIIA homologue 
has been found in the mouse (Gessner et al, 1998).   
 
CONCLUSIONS 
 
Three case-control studies revealed weak but  significant 
associations  between  H131/H131  homozygosity  and  in-
creased P. falciparum morbidity in different populations 
(Omi et al, 2002; Cooke et al, 2003; Brouwer et al, 2004), 
while one study suggested that R131/R131 homozygosity 
may act as a protective factor against high-density parasi-
taemia (Shi et al, 2001). These results are at odds with the 
fact  that  R131  homozygotes  cannot  benefit from  mono-
cyte- or macrophage-mediated effector responses mediated 
by the binding of parasite-specific IgG2 antibodies to the 
H131 allotype of  FcγRIIA (Aucan et al, 2000). The ori-
gins of this apparent contradiction remain unclear; the fine 
balance  between  parasite-killing  and  pro-inflamatory  ef-
fects  of  cytokines  released  by  monocytes  and  macro-
phages, as a consequence of FcγRIIA engagement by anti-
parasite  antibodies  of  different  IgG  subclasses,  may  be 
involved. Additional studies are clearly needed to investi-
gate the magnitude and direction of associations between 
FcγRIIA polymorphism and malaria morbidity in popula-
tions  differing in  genetic  backgrounds  and levels  of  ac-
quired immunity to malaria parasites. 
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LIST OF ABBREVIATIONS 
 
ADCC: antibody-dependent cell-mediated cytotoxicity 
ADCI: antibody-dependent cellular inhibition 
FcR: Fc receptor 
FcεE: receptor for immunoglobulin E Fc 
FcγR: receptor for immunoglobulin G Fc 
H: histidine 
Ig: immunoglobulin 
NK: natural killer  
pRBC: parasitised red blood cells 
R: arginine 
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